Research Article

siRNA is not more Effective than a First Generation Antisense Oligonucleotide when Directed against EGFR in the Treatment of PC-3 Prostate Cancer

PAULUS TSUI, MARVIN RUBENSTEIN and PATRICK GUINAN
In Vivo July 2005, 19 (4) 653-656;

Article Information

vol. 19 no. 4 653-656
PubMed 
15999529
Published By 
International Institute of Anticancer Research
Print ISSN 
0258-851X
Online ISSN 
1791-7549
History 
  • Received May 11, 2005
  • Accepted May 27, 2005
  • Published online July 1, 2005.
Copyright & License 
Copyright © 2005 The Author(s). Published by the International Institute of Anticancer Research.

Author Information

  1. PAULUS TSUI1,
  2. MARVIN RUBENSTEIN1,2 and
  3. PATRICK GUINAN1,3,4
  1. 1Division of Cellular Biology, Hektoen Institute for Medical Research
  2. 2Department of Biochemistry, Rush University Medical Center
  3. 3Department of Urology, Rush University Medical Center
  4. 4Department of Urology, University of Illinois at Chicago, Chicago, IL, 60612, U.S.A.
  1. Correspondence to: Dr. Marvin Rubenstein, Chairman-Division of Cellular Biology, Hektoen Institute for Medical Research, 2100 W. Harrison Street, Chicago, IL, 60612, U.S.A. Tel: 312-864-4621, Fax: 312-948-2509, e-mail: DrMarv{at}Prodigy.net

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
siRNA is not more Effective than a First Generation Antisense Oligonucleotide when Directed against EGFR in the Treatment of PC-3 Prostate Cancer
PAULUS TSUI, MARVIN RUBENSTEIN, PATRICK GUINAN
In Vivo Jul 2005, 19 (4) 653-656;
Twitter logo Facebook logo Mendeley logo

Jump to section

Related Articles

  • No related articles found.

Cited By...

  • No citing articles found.

Similar Articles